These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 18827828)

  • 1. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
    Kazantsev AG; Thompson LM
    Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
    Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creating zinc monkey wrenches in the treatment of epigenetic disorders.
    Kalin JH; Butler KV; Kozikowski AP
    Curr Opin Chem Biol; 2009 Jun; 13(3):263-71. PubMed ID: 19541531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the discovery of small molecule histone deacetylase inhibitors.
    Remiszewski SW
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):487-99. PubMed ID: 12197307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the correct HDAC(s) to treat cognitive disorders.
    Fischer A; Sananbenesi F; Mungenast A; Tsai LH
    Trends Pharmacol Sci; 2010 Dec; 31(12):605-17. PubMed ID: 20980063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
    Butler R; Bates GP
    Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
    Herman D; Jenssen K; Burnett R; Soragni E; Perlman SL; Gottesfeld JM
    Nat Chem Biol; 2006 Oct; 2(10):551-8. PubMed ID: 16921367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
    Hodawadekar SC; Marmorstein R
    Oncogene; 2007 Aug; 26(37):5528-40. PubMed ID: 17694092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer.
    Riester D; Hildmann C; Schwienhorst A; Meyer-Almes FJ
    Anal Biochem; 2007 Mar; 362(1):136-41. PubMed ID: 17250798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc binding in HDAC inhibitors: a DFT study.
    Wang D; Helquist P; Wiest O
    J Org Chem; 2007 Jul; 72(14):5446-9. PubMed ID: 17579460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
    Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
    J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC Inhibitors--CHI's Third Annual Conference.
    Rosato RR
    IDrugs; 2010 Jan; 13(1):13-5. PubMed ID: 20024840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases--an important class of cellular regulators with a variety of functions.
    Hildmann C; Riester D; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
    Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
    Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
    Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.